SGMO - Latest News

Sangamo Therapeutics, Inc. (SGMO), operates in Healthcare / Biotechnology, trades on PNK.

Market capitalization stands near $30.7M. Beta to the broader market is 1.29.

The article list below shows the most recent SGMO headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent SGMO Headlines

Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas

globenewswire.com - Jun 23, 2026

Sangamo intends to complete asset sale transactions through a voluntary Chapter 11 reorganization, in an effort to maximize business value for all sta

Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders

globenewswire.com - Jun 8, 2026

RICHMOND, Calif. , June 08, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc.

Sangamo Therapeutics, Inc. (SGMO) Q1 2026 Earnings Call Transcript

seekingalpha.com - May 14, 2026

Sangamo Therapeutics, Inc.

Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates

zacks.com - May 14, 2026

Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0. 08 per share versus the Zacks Consensus Estimate of a loss of $0.

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results

globenewswire.com - May 14, 2026

Rolling submission of Biologics License Agreement (BLA) to U. S.

How News Affects SGMO Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track SGMO's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.